CUORiPS Inc. announced that it expects to receive ¥2 billion in funding from Asahi Intecc Co., Ltd., StemCell Institute Inc., Dai-Dan Co., Ltd., Taiko Pharmaceutical Co.,Ltd., Kyoto University Innovation Capital Co., Ltd., Terumo Corporation and other investors
December 03, 2020
Share
CUORiPS Inc. announced that it has entered into a agreement for private placements of shares for gross proceeds of ¥2 billion in a round of funding through third party allotment on December 4, 2020. The transaction will include participation from new investors Taiko Pharmaceutical Co.,Ltd. (TSE:4574) for ¥500 million (voting right base 12.4) and StemCell Institute Inc., Asahi Intecc Co., Ltd. (TSE:7747), Dai-Dan Co., Ltd. (TSE:1980) and existing investors Terumo Corporation (TSE:4543) and Kyoto University Innovation Capital Co., Ltd. and other investors.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
CUORiPS Inc. announced that it expects to receive ¥2 billion in funding from Asahi Intecc Co., Ltd., StemCell Institute Inc., Dai-Dan Co., Ltd., Taiko Pharmaceutical Co.,Ltd., Kyoto University Innovation Capital Co., Ltd., Terumo Corporation and other investors
STEMCELL INSTITUTE INC. 
